Vaccination Coverage in Cancer Outpatients: An Interventional Multicenter Before-and-After Study

Pierre Riviere (pierre.rivierepr@gmail.com)
Medical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France
https://orcid.org/0000-0003-2681-091X

Nicolas Penel
Lille University School of Medicine: Universite de Lille Faculte de Medecine and Medical Oncology Department, Centre Oscar Lambret, Lille, France

Karine Faure
Infectious Diseases Department, Lille University Hospital, Lille, France

Guillaume Marie
Medical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France

Abeer Najem
Medical Oncology Department, Boulogne-sur-Mer Hospital, Boulogne-sur-Mer, France

Marie-Karelle Rivière
Paris, France

Sophie Panaget
Infectious Diseases Department, Lille University Hospital, Lille, France

Keywords: vaccination coverage, influenza, Streptococcus pneumoniae, cancer, chemotherapy, medical training

Posted Date: November 15th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-974565/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Journal of Clinical Oncology on May 20th, 2021. See the published version at https://doi.org/10.1200/JCO.2021.39.15_suppl.e24026.
Abstract

Purpose:

Despite widely disseminated guidelines, pneumococcal and influenza vaccination coverage (VC) remains insufficient in cancer patients receiving chemotherapy. We aimed to perform an interventional study to evaluate and improve VC in cancer patients treated in the medical oncology departments of three North-of-France hospitals.

Methods:

A standardized questionnaire assessed VC in adult cancer patients receiving anticancer treatment in three day hospitals from December 2–7, 2019. Subsequently (January 2020), we organized educational training sessions for medical staff in each hospital to discuss the current vaccination guidelines. To assess the impact of training on pneumococcal and influenza VC, we re-administered the same questionnaire in March 2020. Because there were no specific guidelines on Diphtheria-Tetanus-Pertussis (DTP) vaccination and no improvement was expected, DTP VC acted as an internal control.

Results:

In total, 272 patients were enrolled in the “before study” in all three hospitals; 156 patients were enrolled in the “after study” in only two hospitals, as data collection in the third was impossible because of COVID-19 pandemic national containment. The predictors were age for DTP VC, treatment center for pneumococcal VC, and age, sex, and tumor histology (adenocarcinoma vs. others) for influenza VC. Influenza VC was significantly improved post-intervention (42.6% vs. 55.1%, p=0.0169), especially in fragile patients, whereas pneumococcal VC was not (11.8% vs. 15.4%, p=0.3575).

Conclusion:

As expected, VC was very low in cancer patients, consistent with the literature. The intervention’s impact was limited for pneumococcal VC. The increased influenza VC may reflect the result of the national influenza vaccination campaign.

Introduction

In addition to the cancer itself, chemotherapy causes a variable degree of immunosuppression, depending on age, tumor pathology, and the type of chemotherapy, resulting in increased risks of infection, morbidity, and mortality [1]. Vaccination recommendations are intended to reduce morbidity and mortality. Nevertheless, data related to vaccination in patients with solid cancers remain sparse. Furthermore, several studies have included combined populations of patients with solid tumors and hematological malignancies, which differ greatly [2–7]; in addition, some have included patients who were or were not exposed to chemotherapeutic agents [2–4, 7].
Vaccination recommendations for patients undergoing chemotherapy, like the vaccines recommended for the general population, mainly relate to influenza and pneumococcal infection [8]. Guidelines in France also recommend a second vaccine dose for preventing influenza during the peak of the epidemic [9]. Despite these mitigation efforts, 15–20% of patients with influenza require hospitalization [10]. In addition to higher hospitalization rates, immunocompromised individuals may experience mortality rates of up to 50% and delays in chemotherapy schedules. A meta-analysis showed a 70% decrease in the incidence of influenza-like illnesses in vaccinated individuals compared to that in non-vaccinated individuals [2]. A retrospective study of 1,225 patients with colorectal cancer who underwent chemotherapy found a lower incidence of pneumonia, lower mortality at one year, and fewer treatment interruptions in vaccinated than in unvaccinated patients [11].

Despite widely disseminated guidelines, pneumococcal and influenza vaccination coverage (VC) remains insufficient in cancer patients receiving chemotherapy. Several studies have addressed VC issues in cancer patients, particularly for influenza and pneumococcal infection, all of which demonstrated insufficient VC in patients undergoing chemotherapy [3–7, 11–16]. VC against influenza is approximately 30%, whereas that against pneumococcus varies between 5% and 15%. For pneumococcal vaccination, the relative risk of invasive pneumococcal infection in a patient receiving chemotherapy for a solid cancer ranges from 5 [17] to 23 [18]. Even with insufficient VC against pneumococcus, Sangil et al. showed a decrease in the incidence of invasive pneumococcal infections from 20/100,000 to 8/100,000 inhabitants [3].

Improving VC in cancer patients treated with chemotherapy is important for reducing morbidity and mortality; ensuring proper training of medical staff is critical in this setting. Studies in general practice have highlighted feelings among general practitioners that the concern for vaccination falls more on medical oncologists than on themselves [12]. Furthermore, physicians are requesting additional professional training to improve their knowledge about vaccination [4–6]. Thus, we aimed to conduct an interventional, multi-center, before-and-after study to measure the impact of medical staff training on vaccination recommendations to improve pneumococcal and influenza VC in cancer patients. As there is no recommendation for Diphtheria-Tetanus-Pertussis (DTP) vaccination, it served as an internal control.

Methods

We conducted an interventional before-and-after study in medical oncology departments of three North-of-France hospitals. Evaluations occurred before and after providing training to physicians to assess and improve VC in cancer outpatients. The three hospitals were Boulogne-sur-Mer Tertiary Hospital, Lille University Hospital, and Lille Comprehensive Cancer Center (Centre Oscar Lambret).

The first VC assessment occurred over a one-week period from December 2–9, 2019. Between the first and second VC assessments, in January 2020, we organized training sessions with physicians to discuss the current vaccination guidelines. We also provided a vaccination protocol validated by our team of infectious disease specialists.
The second VC assessment occurred in March 2020, eight weeks after the training sessions. Unfortunately, this subsequent evaluation could not be conducted in one of the centers because of the implementation of national containment protocols related to the COVID-19 pandemic.

The same questionnaire, used during each of the two evaluation weeks, assessed the following characteristics at the oncological level: age, sex, World Health Organization (WHO) Performance Status (PS), histological type of cancer, stage (localized or metastatic), primary site, and any ongoing cancer treatment (chemotherapy, hormone therapy, targeted therapy, and immunotherapy). Regarding the evaluation of vaccinations, the questionnaire assessed whether each patient's vaccinations were up-to-date against DTP, seasonal influenza, and pneumococcus. One question that inquired whether the patient's relatives had been contacted to update their vaccinations was misunderstood by some of the participants; therefore, it was excluded from the statistical analyses.

Inclusion/exclusion criteria

The inclusion criteria were as follows: any adult patient undergoing oncological treatment presenting to the day hospital unit during the evaluation week. The exclusion criteria were as follows: any patient who was a minor or who refused to participate in the study and lack of oncological treatment.

The main objective was to assess the VC of patients undergoing anticancer treatment at the three centers. The secondary objectives were to reassess the VC after the physicians underwent the training sessions, to assess the impact of this training, to determine the factors related to VC, and to identify means of improving practices.

Since there were no specific guidelines on DTP vaccination and we did not expect an improvement, DTP VC was used as an internal control.

Ethics

The present study was approved by the Clinical Research and Innovation Department of each treatment center. In accordance with French regulations, this study was approved by the Ethics Committee (Commission Nationale de l'Informatique et des Libertés). Informed consent was obtained from all participants. Authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

An upstream estimation of the number of patients presenting at the day hospitals of each treatment center determined that over one week, 500 patients presented at different centers. We expected an inclusion of 50% of patients per week of assessment.

The completed questionnaires were collected from each center at the end of each evaluation week. Each patient was anonymized to integrate their information into a database and to allow for statistical analysis.

Statistical analysis
Detailed descriptive statistics of the population characteristics were calculated before and after the study. For the determination of VC predictors, data from the before and after study periods were merged. To restrict the number of possible covariates in the multivariate regression models, a pre-selection of potential VC predictors (p<0.20) was performed using univariate logistic regressions for influenza, pneumococcal, and DTP factors. Next, multivariate logistic regression analyses were conducted using a stepwise procedure to identify sets of predictors of VC (p<0.05) for influenza, pneumococcal infection, and DTP. Finally, the impact of intervention (physician training) was evaluated as follows: (a) a test comparing two proportions (before/after) using Pearson's chi-squared test statistic, and (b) logistic regression explaining the vaccination status as a function of the study period (before/after); both approaches were expected to generate concordant results. Interaction terms were considered in the multivariate logistic regression model to explain possible differences in vaccination before and after intervention.

Results

For the “before” period, out of 500 patients presenting at the day hospital, 276 were asked to complete the questionnaire. One patient refused to participate; thus, 275 questionnaires were collected. Of these, 272 were usable. Three questionnaires were excluded from the analyses because they were incomplete. For the “after” period, out of 210 patients presenting at the day hospital, data from 156 patients were included; none refused to participate, and all questionnaires were usable. These data are presented in a flow chart (Figure 1).

The characteristics of the patients included in the “before” and “after” periods of the study are listed in Table 1. In the first evaluation, 272 patients were included, whereas 156 were included in the second. This discrepancy can be explained by the fact that the reassessment could not be completed in one of the centers. The population characteristics were homogeneous for the before and after periods. The median age was 65 years for both evaluations. Equal proportions of male and female patients were included. The repartition of the PS was similar for both evaluations. The primary sites of the lesions were more often in the digestive tract than in the head and neck, breast, or gynecological system. The most common histological types were adenocarcinomas, followed by squamous cell carcinomas and other types. In both evaluations, three-quarters of patients had metastatic cancer. Patients more often received chemotherapy than combined chemo- and targeted therapy, targeted therapy alone, or immunotherapy. These data reveal that even though one of the centers could not participate in the second evaluation, the included patients appeared to be comparable in terms of these characteristics.

The VC results for both time points are presented in Table 2. Before training, the DTP VC was 37.1%, influenza VC was 42.6%, and all patients received an injection in the fall. None of the patients received two injections. The pneumococcal VC was 11.8% (40.6% received an injection of 13-valent conjugate vaccine alone, whereas 59.4% received the full regimen).
After training, the DTP VC was 38.5% and the influenza VC was 55.1%. A total of 91.9% of patients had received an injection in the fall, whereas 8.1% of patients received the injection in the winter; none received two injections. The pneumococcal VC was 15.4% (16.7% received an injection of 13-valent conjugate vaccine alone, whereas 83.3% received the complete regimen).

For influenza VC, age (p<0.0001), sex (p=0.0036), and histologic type (p=0.0128) were identified as predictors by the multivariate logistic regression analyses. As expected, older patients, as they are more fragile, were vaccinated at significantly higher rates for influenza. In addition, those patients satisfy two of the criteria for which vaccination is recommended in an organized global campaign, including receiving cancer treatment and being older than 65 years old. Men were vaccinated at significantly higher rates for influenza than women, which may be owing to other comorbidities, such as diabetes, obesity, and organ failure, that were not considered in our study. We also noted that the histologic type of cancer was a significant predictor (adenocarcinoma vs. others).

For pneumococcal VC, we only observed an effect related to the treatment center (p<0.0001). Patients from one center tended to be vaccinated at higher rates than those from the other two centers.

Age was identified as a predictor for DTP VC. There is no specific recommendation for DTP vaccination in patients undergoing anticancer treatment. These patients, identified as being more fragile, may have been vaccinated by their general practitioner.

The focus of the impact of the intervention (physicians’ training) was on influenza and pneumococcus VC. A test comparing the two proportions of vaccinated patients before and after the intervention was performed. A significant effect of intervention was observed for influenza (p=0.0169), but not for pneumococcal infection (p=0.3575). As we performed two tests, corrected p-values were used to account for multiplicity. The conclusions did not differ for influenza (p=0.0338) nor pneumococcal infection (p=0.715) when using the Bonferroni correction, which is more stringent. Thus, the intervention was more effective in increasing influenza VC.

We also constructed a logistic regression model to explain the vaccination status as a function of the study period (before or after) to determine the impact of the intervention. The results led to the same conclusions, namely that influenza VC was significantly higher after the intervention (p=0.0127), whereas the VC for pneumococcal infection was unaffected (p=0.2860).

By including interaction terms in the logistic model, patients with a higher WHO PS showed significantly higher vaccination rates than patients with a lower PS after the intervention. It is possible that oncologists recommend influenza vaccination more strongly to those that are observed to be in poor condition (Figure 2).

Discussion
Our study confirms that VC is low in patients with solid tumors. Before training, DTP, influenza, and pneumococcal VC were 37.1%, 42.1%, and 11.8%, respectively, whereas after training, they were 38.5%, 42.1%, and 15.4%, respectively. No patient received two injections of vaccine against influenza. The predictor for DTP VC was age; for influenza VC, the predictors were age, sex, and histological type. Our analysis highlighted a significant improvement in VC after the intervention, especially in patients with poor PS, but only for influenza, not for pneumococcal infection.

Our results are consistent with those in the literature [3–5, 12, 19, 20]. Despite improvement, the VC before and after the intervention remained low. Regarding DTP, the VC in this study was comparable to that in other cancer studies and in the general population. A recent study by Monier et al. [7] found a DTP VC of 33.1% in oncology patients. In comparison, in a survey conducted by the Sanitary Surveillance Institute (Institut National de Veille Sanitaire) in January 2011, 44% of patients over 65 years of age were vaccinated against DTP in the general population [21].

In our study, the VC of influenza was higher than that reported by most investigations in medical oncology patients [4, 5, 7, 11, 12, 14, 15]. However, this difference cannot be explained by age because in the other studies, half of the participants were also over 65 years old and, therefore, had another indication for receiving influenza vaccinations. In a study by Alkan et al., factors associated with a low VC against influenza were age below 65 years, insufficiently informed oncologist, and doubts about the effectiveness of the vaccine among medical staff [19]. However, in a study conducted by Toleman et al. on cancer patients in the UK, influenza VC was 68.1% [20]. In France, a free influenza vaccination campaign is conducted yearly from early October to late February. Eligible patients targeted for vaccination are those at risk of complications: pregnant women, patients aged 65 years and older, patients with chronic diseases, immunocompromised patients and their relatives, obese patients, patients living in a healthcare institution, group or cruise ship travelers, and healthcare professionals. During the 2019–2020 influenza vaccination campaign, the VC for high-risk patients was 47.80% (31% before age 65 and 52% after age 65) [22].

In our study pneumococcal VC was comparable to that in other studies, approximately 5–15% in patients with cancer [5, 7, 16]. However, other studies have found a higher pneumococcal VC. For example, Toleman et al. reported a pneumococcal VC of approximately 25% in those receiving treatment for cancer [20]. In another study that evaluated the VC of 429 non-cancer patients at high risk of infections (i.e., those with diabetes, HIV, transplantation, heart failure, chronic kidney disease, solid organ transplantation, and chronic obstructive pulmonary disease), the pneumococcal VC was 32%, which is higher than the value in the present study [23].

Overall, our study found that medical staff training did not improve VC in cancer patients. Toleman et al. also conducted a before-and-after study of VC after dissemination of recommendations for vaccination [20]. They found that influenza VC increased from 71.6% at the first reassessment (January 2013) to 72.7% at the second (April 2014), a change that was not statistically significant. For pneumococcus, the VC increased from 25% to 47.7% at the first reassessment and was 33.6% at the second. Thus, there was
a significant difference at the first reassessment for pneumococcus, although the study’s findings were negative at two years.

Our study has several limitations. First, it only assessed the early impact of the training sessions 8 weeks after the initial assessment at only two of the three centers due to the COVID-19 pandemic and the national containment procedures. The assessment after the intervention was initially postponed in that center, although it ultimately did not occur to avoid the risk of measurement bias. Delaying the training in the third center could have modified the reassessment of seasonal influenza VC since the influenza epidemic and the national vaccination campaign would have been completed long before the evaluation. There could also have been biases for pneumococcal VC if we reevaluated the effect in the third center at a later time. Indeed, during the containment period, two phenomena were observed. On one hand, face-to-face consultations were canceled or postponed, the number of telehealth consultations increased, and chemotherapy courses were administered less frequently, which reduced the opportunity for dissemination of vaccination information and the offer to be vaccinated. On the other hand, some physicians assumed that a pneumococcal vaccine could help protect against COVID-19 infection and proposed such vaccinations as a preventative measure [24–26]. Although our assessment of the intervention’s effect in the third center is incomplete, this remains a multicenter study comprising hospitals with different characteristics.

Second, we considered patients to be vaccinated against pneumococcal infection if they had received an injection of either a 13-valent conjugate vaccine or the full regimen. Data from a later assessment (beyond 8 weeks) could be more clinically relevant. Nevertheless, it seemed relevant to begin by assessing the early effects following the initiation of this regimen by clinicians.

Third, all patients currently receiving systemic cancer treatments in the day hospital (chemotherapy, immunotherapy, and molecularly targeted therapies) were included. Even if the current recommendations focused on patients exposed to chemotherapy, we decided to include all patients seen at the day hospital for several reasons. First, most patients had metastatic cancer and, therefore, had received or will receive chemotherapy. Patients with localized cancer seen at day hospitals currently receive (neo)adjuvant chemotherapy. Patients receiving only hormonal therapies were not included, as they were managed in consultation rather than in the day hospital. Specific recommendations for cancer patients receiving treatment other than chemotherapy are pending and should be published soon. Some data, however, have already been published; for example, recent studies have found a safe and effective influenza vaccine for patients receiving tyrosine kinase inhibitors [27] and immunotherapy [28, 29].

To improve VC, it is necessary to consider everyone’s perceived risk of infection. For example, it may be difficult for physicians or patients to perceive the benefits of pneumococcal vaccination. In fact, the annual incidence of invasive pneumococcal disease ranges from 10–100 cases per 100,000 inhabitants [30]. Even with a relative risk between 5 and 23, infection can be considered a rare event.

Other solutions need to be discussed to improve VC in patients with cancer. First, the involvement of general practitioners must improve, as many patients trust their general practitioner, and general
practitioners ask for better vaccination training. The COVID-19 pandemic has shown that many general practitioners favor better collaboration between the city and the hospital. For specialized subjects, optimizing the management of certain pathologies may require better two-way communication. Our training regimen and protocol could help general practitioners improve practices and communication.

Second, the establishment of enhanced cooperation between oncologists and infectious disease specialists can increase VC through dedicated consultation or remote expertise. Our study assessed the VC of patients undergoing cancer treatment, but not the knowledge of the oncologist or the application of vaccine recommendations. Thus, prescribing a vaccine does not always ensure its administration, and clear accurate information should be provided at a dedicated time. In medical oncology, finding this time can be difficult. There are three main types of consultations: announcement, day hospital, and follow-up consultations. Discussing vaccination during these consultations is complicated; thus, it seems essential to involve another physician in the circuit during in-person or tele-medicine consultations dedicated to vaccination discussions. Sitte et al.'s prospective cohort study showed that a specialized infectious disease consultation can improve gastrointestinal cancer and inflammatory bowel disease patients' VC [31]. Recently, the implementation of a pre-renal transplant consultation improved VC and patient compliance, with only two refusals of vaccination in 467 patients [32].

Third, our training was intended to help physicians take care of patients. We could have involved other health professionals who work as closely as possible with patients, such as nurses. The establishment of a consultation with a nurse in a day hospital could focus on infectious issues, including fever, febrile neutropenia, catheter-related infection, and vaccinations. Another possibility would be to involve the entourage to ensure better adherence. Finally, pre-established prescriptions or an immunization page could be included in the personalized patient care plan or an insert at the bottom of letters to the attending physician. In a study by Toleman et al., the intervention consisted of training oncologists and using emails as reminders and for dissemination of recommendations via intranet and posters in day hospitals. Information was also sent to general practitioners (email) and patients (letters). Involving all health professionals is optimal.

A longitudinal evaluation of VC at later time points after training and studies with larger sample sizes could verify an absence or lack of improvement in VC. It would be interesting to reassess the VC during the next winter season following the implementation of the proposals. Indeed, the COVID-19 pandemic has changed the perception of the importance of vaccination.

Over time, there has been an improvement in the survival and implementation of new therapies, although the number of immunodeficient patients has increased. This is the origin of an increase in the transmission of vaccine-preventable diseases, and everyone must be involved in the fight against these diseases with the help of vaccination.

Conclusion

Evaluations of the VC of cancer patients receiving treatment revealed a low VC for DTP, influenza, and pneumococcus during both the first and second evaluation periods. Our intervention did not improve the VC against pneumococcus; however, significant improvement of the VC against influenza was observed,
especially in patients with a poor WHO PS, although there may have been unmeasured cofounders. This increased VC may reflect the results of the national influenza vaccination campaign. The findings provide a basis for the concrete implementation of actions aimed at improving VC in the three centers.

**Declarations**

**Acknowledgements**

We would like to thank the participating centers for their involvement in this project.

Additionally, we would like to thank Editage (www.editage.com) for English language editing.

**Funding:**

The authors did not receive support from any organization for the submitted work.

**Conflicts of Interest:**

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.

**Availability of Data and Material:**

Data may be accessed in the clinical research department of each center.

**Code availability:**

R Core Team (2021). R: A language and environment for statistical computing.

R Foundation for Statistical Computing, Vienna, Austria.

URL https://www.R-project.org/

**Authors’ Contributions:**

Conceptualization: Pierre Rivière, Sophie Panaget, Resources: Pierre Rivière, Sophie Panaget, Methodology: Marie-Karelle Rivière, Implementation of study: Pierre Rivière, Karine Faure, Guillaume Marie, Abeer Najem, Nicolas Penel, Data collection: Pierre Rivière, Statistical analysis: Marie-Karelle Rivière, Medical training: Pierre Rivière, Sophie Panaget, Writing- original draft preparation: Pierre Rivière, Writing- review and editing: all authors

**Ethics Approval:**

The present study was approved by the Clinical Research and Innovation Department of each treatment center. In accordance with French regulations, this study was approved by the Ethics Committee (Commission Nationale de l’Informatique et des Libertés). Informed consent was obtained from all
participants. Additionally, authors certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

**Consent to Participate:**

Informed consent was obtained from all individual participants included in the study.

**Consent for publication:**

Informed consent was obtained from all individual participants included in the study.

**References**

1. Mackall CL (2000) T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Stem Cells (Dayton, Ohio) 18:10-18. [https://doi.org/10.1634/stemcells.18-1-10](https://doi.org/10.1634/stemcells.18-1-10)

2. Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group, Nguyen-Van-Tam JS (2012) Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 206:1250-1259. [https://doi.org/10.1093/infdis/jis487](https://doi.org/10.1093/infdis/jis487)

3. Sangil A, Xercavins M, Rodríguez-Carballeira M, Andrés M, Riera M, Espejo E, Pérez J, Garau J, Calbo E (2015) Impact of vaccination on invasive pneumococcal disease in adults with focus on the immunosuppressed. J Infect 71:422-427. [https://doi.org/10.1016/j.jinf.2015.07.004](https://doi.org/10.1016/j.jinf.2015.07.004)

4. Poeppl W, Lagler H, Raderer M, Sperr WR, Zielinski C, Herkner H, Burgmann H (2015) Influenza vaccination perception and coverage among patients with malignant disease. Vaccine 33:1682–1687. [https://doi.org/10.1016/j.vaccine.2015.02.029](https://doi.org/10.1016/j.vaccine.2015.02.029)

5. Urun Y, Akbulut H, Demirkazik A, Cay Senler F, Utkan G, Onur H, Icli F (2013) Perception about influenza and pneumococcal vaccines and vaccination coverage among patients with malignancies and their family members. J BUON 18:511–515. PMID: 23818370

6. Glavier M, Puyade M, Puyade F, Rammaert B (2019) Vaccination of cancer patients treated with chemotherapy: A survey among general practitioners. Med Mal Infect 49:586–592. [https://doi.org/10.1016/j.medmal.2019.09.004](https://doi.org/10.1016/j.medmal.2019.09.004)

7. Monier A, Puyade M, Hernanz MPG, Bouchaert P, Leleu X, Tourani JM, Roblot F, Rammaert B (2020) Observational study of vaccination in cancer patients: how can vaccine coverage be improved? Med Mal Infect 50:263-268. [https://doi.org/10.1016/j.medmal.2019.11.006](https://doi.org/10.1016/j.medmal.2019.11.006)

8. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I (2013) IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:309-318. [https://doi.org/10.1093/cid/cit684](https://doi.org/10.1093/cid/cit684)

9. HCSP (2014) Vaccination des personnes immunodéprimées ou aspléniques. Recommandations actualisées. Rapport du HCSP. Haut Conseil de la Santé Publique, Paris.
10. Mauskopf J, Klesse M, Lee S, Herrera-Taracena G (2013) The burden of influenza complications in different high-risk groups: a targeted literature review. J Med Econ 16:264-277. https://doi.org/10.3111/13696998.2012.752376

11. Earle CC (2003) Influenza vaccination in elderly patients with advanced colorectal cancer. J Clin Oncol 21:1161-1166. https://doi.org/10.1200/JCO.2003.06.008

12. Wumkes ML, van der Velden AMT, van der Velden AWG, Stouthard JML, Nijziel MR, Westerman M, Beeker A, Meerveld-Eggink A, Rijkers GT, Biesma DH (2013) Influenza vaccination coverage in patients treated with chemotherapy: current clinical practice. Neth J Med 71:472-477. PMID: 24218421

13. Janssen C, Girod N, Vaquier F, Orsini F, Reynes C, Daguindau N, Chabrot C, Gerbaud L, Jund J (2017) HEMAVAC – évaluation de la couverture vaccinale des patients en hémato logie sous chimiothérapie. Med Mal Infect 47(4):S129-S130. https://doi.org/10.1016/j.medmal.2017.03.313

14. Ring A, Marx G, Steer C, Prendiville J, Ellis P (2003) Poor uptake of influenza vaccinations in patients receiving cytotoxic chemotherapy. Int J Clin Pract 57:542–543. PMID: 12918895

15. Loulergue P, Mir O, Alexandre J, Ropert S, Goldwasser F, Launay O (2008) Low influenza vaccination rate among patients receiving chemotherapy for cancer. Ann Oncol 19:1658. https://doi.org/10.1093/annonc/mdn531

16. Risso K, Naqvi A, Pillet S, Leplatois A, Pulcini C (2010) Insufficient pneumococcal vaccine coverage in adult inpatients at risk. Med Mal Infect 40:341-346. https://doi.org/10.1016/j.medmal.2009.12.004

17. Klemets P, Lyytikäinen O, Ruutu P, Ollgren J, Kaijalainen T, Leinonen M, Nuorti JP (2010) Risk of invasive pneumococcal infections among working age adults with asthma. Thorax 65:698-702. https://doi.org/10.1136/thx.2009.132670

18. Kyaw MH, Rose CE, Fry AM, Singleton JA, Moore Z, Zell ER, Whitney CG (2005) The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis août 192:377-386. https://doi.org/10.1086/431521

19. Alkan A, Karcı E, Yaşar A, Tuncay G, Kökösoy EB, Ürün M, Şenler FÇ, Demirkazık A, Utkan G, Akbulut H, Ürün Y (2017) Vaccination in oncology practice and predictors. Support Care Cancer 25:2677-2682. https://doi.org/10.1007/s00520-017-3675-y

20. Toleman MS, Herbert K, McCarthy N, Church DN (2016) Vaccination of chemotherapy patients—effect of guideline implementation. Support Care Cancer 24:2317-2321. https://doi.org/10.1007/s00520-015-3037-6

21. Institut de Veille Sanitaire (2011) Enquête nationale de couverture vaccinale, France. 2011. https://www.santepubliquefrance.fr/content/download/181715/2304769

22. Données de couverture vaccinale grippe par groupe d’âge (2021). Santé publique France. https://www.santepubliquefrance.fr/determinants-de-sante/vaccination/donnees-de-couverture-vaccinale-grippe-par-groupe-d-age
23. Boey L, Bosmans E, Ferreira LB, Heyvaert N, Nelen M, Smans L, Tuerlinckx H, Roelants M, Claes K, Derdelinckx I, Janssens W, Mathieu C, Van Cleemput J, Vos R, Vandermeulen C (2020) Vaccination coverage of recommended vaccines and determinants of vaccination in at-risk groups. Hum Vaccin Immunother 16:2136-2143. https://doi.org/10.1080/21645515.2020.1763739

24. Thindwa D, Garcia Quesada M, Liu Y, Bennett J, Cohen C, Knoll MD, von Gottberg A, Hayford K, Flasche S (2020) Use of seasonal influenza and pneumococcal polysaccharide vaccines in older adults to reduce COVID-19 mortality. Vaccine 38:5398-5401. https://doi.org/10.1016/j.vaccine.2020.06.047

25. Sultana J, Mazzaglia G, Luxi N, Cancellieri A, Capuano A, Ferrajolo C, de Waure C, Ferlazzo G, Trirò G (2020) Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Rev Vaccines 19:919-936. https://doi.org/10.1080/14760584.2020.1825951

26. Root-Bernstein R (2020) Possible cross-reactivity between SARS-CoV-2 proteins, CRM197 and proteins in pneumococcal vaccines may protect against symptomatic SARS-CoV-2 disease and death. Vaccines 8:E559. https://doi.org/10.3390/vaccines8040559

27. Mulder SF, Jacobs JFM, Olde Nordkamp MAM, Galama JMD, Desar IME, Torensma Teerenstra S, Mulders PFA, Vissers KCP, Punt CJA, de Vries IJM, van Herpen CML (2011) Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res Off J Am Assoc Cancer Res. 1 juill 17:4541-4549. https://doi.org/10.1158/1078-0432.CCR-11-0253

28. Bayle A, Khettab M, Lucibello F, Chamseddine AN, Goldschmidt V, Perret A, Ropert S, Scotté F, Loulergue P, Mir O (2020) Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Annals of Oncology 31:959–961. https://doi.org/10.1016/j.annonc.2020.03.290

29. Chong CR, Park VJ, Cohen B, Postow MA, Wolchok JD, Kamboj M (2020) Safety of inactivated influenza vaccine in cancer patients receiving immune checkpoint inhibitors. Clin Infect Dis. Off Publ Infect Dis Soc Am 2 Jan 70(2):193–199. https://doi.org/10.1093/cid/ciz202

30. World Health Organization (23 Mar 2007) Pneumococcal conjugate vaccine for childhood immunization – WHO position paper. Wkly Epidemiol Rec 82:93–104. https://apps.who.int/iris/handle/10665/240901

31. Sitte J, Frentiu E, Baumann C, Rousseau H, May T, Bronowicki JP, Peyrin-Biroulet L, Lopez A (2019) Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage. Aliment Pharmacol Ther. 2019 Jan,49(1):84-90. https://doi.org/10.1111/apt.15057

32. Runyo F, Matignon M, Audureau E, Gomart C, Boueihl A, Vindriès W, Grimbert P, GallienS, Melica G (2020) La consultation d’infectiologie avant transplantation rénale est un moyen d’optimiser la prévention vaccinale et le traitement de la tuberculose latente: une étude de cohorte prospective. Med Mal Infect 50(6):S1617. https://doi.org/10.1016/j.medmal.2020.06.039
Tables

Table 1: Characteristics of the patients included in the before-and-after studies.
|                                | Before Study (N=272) | After Study (N=156) |
|--------------------------------|----------------------|---------------------|
| **Age (years)**                |                      |                     |
| Mean (Standard Deviation)      | 63.4 (11.8)          | 63.9 (11.3)         |
| Median                         | 65.0                 | 65.0                |
| Minimum, Maximum               | 21, 91               | 36, 87              |
| **Age by age group (years) [n (%)]** |                      |                     |
| <65                            | 132 (48.5)           | 77 (49.4)           |
| ≥65                            | 140 (51.5)           | 79 (50.6)           |
| **Sex [n (%)]**                |                      |                     |
| Female                         | 143 (52.6)           | 77 (49.4)           |
| Male                           | 129 (47.4)           | 79 (50.6)           |
| **World Health Organization Performance Status [n (%)]** |                      |                     |
| 0                              | 103 (37.9)           | 40 (25.6)           |
| 1                              | 141 (51.8)           | 97 (62.2)           |
| 2                              | 28 (10.3)            | 19 (12.2)           |
| **Primary site [n (%)]**       |                      |                     |
| CUP                            | 1 (0.4)              | 1 (0.6)             |
| Brain                          | 0 (0.0)              | 1 (0.6)             |
| Digestive tract                | 134 (49.3)           | 83 (53.2)           |
| Gynecological system           | 36 (13.2)            | 16 (10.3)           |
| Head and Neck                  | 38 (14.0)            | 22 (14.1)           |
| Bone                           | 1 (0.4)              | 0 (0.0)             |
| Skin                           | 0 (0.0)              | 1 (0.6)             |
| Pleura                         | 1 (0.4)              | 0 (0.0)             |
| Location                  | Count (Percentage)  | Count (Percentage) |
|---------------------------|---------------------|-------------------|
| Lung                      | 13 (4.8)            | 0 (0.0)           |
| Breast                    | 35 (12.9)           | 25 (16.0)         |
| Soft Tissue               | 2 (0.7)             | 0 (0.0)           |
| Urologic system           | 11 (4.0)            | 7 (4.5)           |

| Histological type [n (%)] |
|---------------------------|
| Adenocarcinoma            | 180 (66.2)          | 104 (66.6)        |
| Squamous cell carcinoma   | 54 (19.9)           | 26 (16.7)         |
| Others                    | 38 (13.9)           | 26 (16.7)         |

| Stage of the disease [n (%)] |
|-----------------------------|
| Localized                   | 81 (29.8)           | 40 (25.6)         |
| Metastatic                  | 191 (70.2)          | 116 (74.4)        |

| Treatment [n (%)]           |
|-----------------------------|
| Chemotherapy                | 172 (63.2)          | 103 (66.0)        |
| Chemotherapy + Immunotherapy| 0 (0.0)             | 1 (0.7)           |
| Chemotherapy + Radiotherapy | 3 (1.1)             | 0 (0.0)           |
| Chemotherapy + Targeted therapy| 47 (17.3)     | 25 (16.0)         |
| Hormone therapy + Targeted therapy| 1 (0.4)      | 0 (0.0)           |
| Immunotherapy               | 20 (7.4)            | 5 (3.2)           |
| Targeted therapy            | 29 (10.7)           | 22 (14.1)         |

| Center [n (%)]               |
|-----------------------------|
| Tertiary hospital           | 94 (34.6)           | 75 (48.1)         |
| University hospital         | 67 (24.6)           | 81 (51.9)         |
| Comprehensive cancer center | 111 (40.8)          | 0 (0.0)           |

Abbreviation: CUP, Carcinoma of Unknown Primary
Table 2: VC of the before-and-after studies.

|                               | Before Study (N=272) | After Study (N=156) | Uncorrected p-values (Before vs After Study) with χ² test |
|-------------------------------|----------------------|---------------------|----------------------------------------------------------|
| **DTP VC [n (%)]**           |                      |                     |                                                          |
| Yes                           | 101 (37.1)           | 60 (38.5)           |                                                          |
| No                            | 171 (62.9)           | 96 (61.5)           |                                                          |
| **Influenza VC [n (%)]**     |                      |                     | 0.0169                                                   |
| Yes                           | 116 (42.6)           | 86 (55.1)           |                                                          |
| In the fall                   | (100.0)              | (91.9)              | 79                                                       |
| At least one injection        | (100.0)              | (100.0)             | 86                                                       |
| Revaccinated if endemic period| (0.0)                | (0.0)               | 0                                                        |
| No                            | 156 (57.4)           | 70 (44.9)           |                                                          |
| **Pneumococcal VC [n (%)]**  |                      |                     | 0.3575                                                   |
| Yes                           | 32 (11.8)            | 24 (15.4)           |                                                          |
| 13-valent conjugate only      | (40.6)               | (16.7)              | 4                                                        |
| Full regimen completed        | (59.4)               | (83.3)              | 20                                                       |
| No                            | 240 (88.2)           | 132 (84.6)          |                                                          |

Abbreviations: DTP, Diphtheria-Tetanus-Pertussis, VC, vaccination coverage
Figure 1

Flow chart of the number of patients included in the before and after studies
Influenza VC by WHO Performance Status

**Figure 2**

Influenza VC by WHO PS and study period. Abbreviations: VC, vaccination coverage, WHO PS, World Health Organization Performance Status